The SABE belle BIOMALIFE® BUTIRBIOMA tablets are a dietary supplement based on sodium butyrate. Each tablet contains 625 mg of modified-release sodium butyrate.
€24.70
Content:
30 Stück
(€0.82 / 1 Stück)
(May vary by country)
Available, delivery time: 1-3 days ⁴
Product number:
RA8078243
Stück:
Manufacturer:
SABE belle
Product information "SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets"
The SABE belle BIOMALIFE® BUTIRBIOMA tablets are a dietary supplement based on sodium butyrate. Each tablet contains 625 mg of modified-release sodium butyrate
The intestinal barrier
- The intestinal barrier is the largest interface and contact surface between our organism and the outside world. It functions as an extremely precise, active filter and protective mechanism and distinguishes nutrients and beneficial substances from potentially harmful antigens and microorganisms. The epithelium is the centrepiece of the intestinal barrier. This consists of the intestinal cells, which are firmly connected to each other by tight junctions, and the protective mucus layer that covers and protects these cells.
- Various factors can damage the intestinal barrier: The protective mucus layer becomes thinner and is absent or interrupted in places; the tight junctions open up and spaces are created between the cells (leaky gut syndrome).
- These gaps allow antigens, toxins and bacteria to penetrate the intestinal barrier and enter the gut-associated immune system (GALT). The GALT reacts to these foreign bodies and activates immune cells that secrete pro-inflammatory substances. This inflammation of the intestine exacerbates the already existing disruption of the intestinal barrier, as if in a vicious circle.
Active ingredients
Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid produced during the microbial fermentation of dietary fibre in the intestine. Butyrate is the favoured food and energy source of the cells that form the intestinal barrier.
It has a dual effect:
- it helps to maintain the intestinal barrier by acting on the tight junctions that hold the intestinal cells together;
- it stimulates the production of mucus, which coats and protects the intestinal cells.
Areas of application
- iBS - irritable bowel syndrome (with constipation, diarrhoea, irregular bowel movements)
- CED - Crohn's disease and ulcerative colitis
- Diverticular disease
- Coeliac disease
- Recurrent diarrhoea
- Traveller's diarrhoea
- Food intolerances
- Pharmacological treatments (to prevent diarrhoea)
- Flatulence and intestinal discomfort (after antibiotic therapy)
- Discomfort following a colonoscopy (2 tablets daily 1 week before & 1 tablet daily 1 week after)
- Recurrent Candida infections
Indications
- Gluten-free
- Naturally lactose-free
- Without sweeteners
- No added sugar
- No preservatives
- M. Cuff, J. Dyer, M. Jones e al, "The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis," Gastroenterology, vol. 128, n. 3, pp. 676-686, 2005. - C. Kelly, L. Zheng, E. Campbell e al, "Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function," Cell Host Microbe, vol. 17, n. 5, p. 662-671, 2015. - A. Dilly, Y. Lee, H. Zeh e al, "Targeting Hypoxia-Mediated Mucin 2 Production as a Therapeutic Strategy for Mucinous Tumours," Transl Res, vol. 169, pp. 19-30, 2016. - L. Peng, Z. Li, R. Green e al, "Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers," J Nutr, vol. 139, pp. 1619-1625, 2009. - T. Banasiewicz, E. Kaczmarek, J. Maik e al, "Quality of life and the clinical symptoms at the patients with irritable bowel syndrome treated complementary with protected sodium butyrate," Gastroenterol Prakt, vol. 5, pp. 45-53, 2011. - T. Banasiewicz, E. Kaczmarek, J. Maik e al, "The influence of protected sodium butyrate on frequency and severity of some clinical symptoms at the patients with irritable bowel syndrome," Gastroenterol Prakt, vol. 1, pp. 16-23, 2012. - E. Scarpellini, E. Lauritano, A. Lupascu e al, "Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome," Dig Liver Dis, pp. 19-22, 2007. - W. Tarnowski, K. Borycka-Kiciak, A. Kiciak e al, "Outcome of treatment with butyric acid In irritable bowel syndrome - preliminary report," Gastroenterol Prakt, vol. 1, pp. 43-48, 2011. - L. Krokowicz, Z. Stojcev, B. Kaczmarek e al, "Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of study," Int J Colorectal Dis, vol. 29, n. 3, pp. 387-393, 2014.
Dosage form
Gastro-resistant tablets
How to use
- Take up to 3 tablets daily, preferably during a meal, with a little water. The product can be taken for several months
- Advice: Suitable for children from 6 years of age. During pregnancy and breastfeeding. The tablets must not be crushed or ground but must be taken whole.
Ingredients
- Ingredients: SODIUM BUTYRATE, STABILISER: HYDROXYPROPYL METHYLCELLULOSE; ACIDITY REGULATOR: CALCIUM CARBONATE; GLAZING AGENTS: ETHYLCELLULOSE, HYDROXYPROPYLCELLULOSE, TALC, SODIUM ALGINATE, MEDIUM-CHAIN TRIGLYCERIDES, POLYETHYLENE GLYCOL, FATTY ACIDS; FIRMING AGENT: SORBITOL; ACIDITY REGULATOR: CALCIUM HYDROXIDE; MAIZE STARCH; ANTI-CAKING AGENT: CALCIUM SALTS OF FATTY ACIDS, SILICON DIOXIDE; COLOUR: CALCIUM CARBONATE; THICKENER: GUAR GUM, SODIUM ALGINATE.
- Composition per 1 tablet: sodium butyrate 625 mg of which butyrate 500 mg.
| Gluten-free: | Yes |
|---|---|
| Lactose-free: | Yes |
| Piece: | 30 |
| Vegetarian: | Yes |
Read more
No reviews found. Share your insights with others.
Warnings - SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets
Instructions for use
Product recommendations for you